InVivo Biosystems

🚀 Register now before it's too late! BioReperia and InVivo Biosystems are teaming up for an exclusive, live webinar that will take you deep into the innovative world of zebrafish models in disease research! 🌊 Why zebrafish? These remarkable models are revolutionizing how we tackle complex diseases such as cancer. Traditional models can fall short, but zebrafish—through genome editing and tumor xenografts—offer an accelerated, predictive pathway to understanding disease mechanisms and pioneering new therapies. 📅 Don’t miss your chance to see how zebrafish are changing the game in drug discovery and precision medicine. Register today and explore a new frontier in biomedical research! 🔗 Register here: https://bit.ly/3NWJRKc #Pharma #Biopharma #Preclinical #DiseaseResearch #Zebrafish #Xenografts

📢 Webinar Alert - BioReperia and InVivo Biosystems are teaming up for an exclusive co-hosted webinar! 🌟 Join us for a live, interactive session where you’ll discover the groundbreaking potential of zebrafish models in unraveling human disease mechanisms and advancing innovative treatments through genome editing and tumor xenograft models. While molecular biology has made impressive strides in disease understanding, translating these findings into effective therapies—especially for complex conditions like cancer—remains a challenge. Traditional rodent and cell-based models have limitations that delay clinical timelines. Now, thanks to recent advancements, zebrafish have emerged as a game-changing alternative in disease research, drug screening, and precision medicine. Reserve your spot now to see firsthand how zebrafish models are transforming the landscape of biomedical research. This is a session you won’t want to miss! Register Here: https://lnkd.in/gB_FVr9T #pharma #biopharma #preclinical #diseaseresearch #zebrafish #xenografts

🚀 Last week, the InVivo Biosystems team had the incredible opportunity to attend the Precision Evolution Global Drug Discovery & Preclinical Summit, a game-changing event where our very own Sarah Cheesman, Ph.D., VP of Strategic Partnerships, moderated an expert panel on overcoming bottlenecks to attaining IND approval — a critical topic for revolutionizing the path to new therapies. We were thrilled to find that so many attendees were already aware of the power of zebrafish and 𝘊. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴 as valuable models in preclinical development! 🐟🪱 These models are truly gaining recognition for their potential to accelerate drug discovery and provide earlier insights into therapeutic efficacy and safety. On top of that, we made fantastic new connections and came away energized to continue advancing research with our 𝑹𝒂𝒑𝒊𝒅𝑮𝒆𝒏™ 𝒑𝒍𝒂𝒕𝒇𝒐𝒓𝒎, pushing the frontiers of preclinical testing. Here’s to continuing the momentum and working together to bring innovative solutions to life! 💡 #DrugDiscovery #PreclinicalResearch #Pharma #Biopharma #Zebrafish #Celegans #Biotech #Innovation #InVivoBiosystems #RapidGen #PrecisionEvolutionSummit

⬇ Happening now at the #PDDPSUMMIT in #SANDIEGO Our rockstar panel moderated by Sarah Cheesman, Ph.D. of InVivo Biosystems is discussing Navigating the Complexities: Challenges in Advancing Drug Candidates to the IND Stage Joined by the panelists: Sanjeev Thohan, Elisabeth Gardiner and Andrea Small-Howard, PhD, MBA. Email us at info@Precision-globe.com to learn about tomorrow's line up of speakers and panel at the #PDDPSUMMIT #DrugDiscovery #Preclinical #AI #ML #Data #events #Summits #Conferences #DigitalHealth #DrugDevelopment #Molecules #protein #Antibodies #Therapeutics #ClinicalResearch #INDStage #CRO #Innovation

🌟 Employee Spotlight: Melissa Hinman, Ph.D. 🌟 Meet Dr. Melissa Hinman, a key member of our scientific team at InVivo Biosystems. Melissa designs and builds transgenic zebrafish models that power groundbreaking research and preclinical development. 🧬 With a Ph.D. in Genetics and Genome Sciences from Case Western Reserve University, Melissa’s deep expertise is the foundation for her innovative work today. Melissa’s journey in genetics began at Whitworth University, where she earned degrees in biology and Spanish. After her Ph.D., she completed her postdoctoral research at the Institute of Molecular Biology at the University of Oregon—the birthplace of zebrafish research. Her extensive academic background in genetics has given Melissa a unique blend of technical expertise and creative problem-solving skills, which she applies every day at InVivo Biosystems. She is one of our most versatile team members, with end-to-end involvement in projects including transgenic design (knock outs, knock ins, Tol2), zebrafish phenotyping, and more. She is also a tender of plants, contributes sweet goods to the community kitchen on site at IVB and has recently taken up rock climbing. Melissa recently received a well-deserved shout-out from one of our clients who happens to be at her alma mater. Her recent project for Whitworth University involved developing a technically challenging transgenic zebrafish line for a client’s research in protein function. At InVivo Biosystems, we’re proud to have talented scientists like Melissa leading the charge in advancing research through the development of custom genetic models. Her passion for science and drive for innovation are what make her—and our whole team—so exceptional! 🌟 Link to Whitworth University’s post highlighting Melissa: https://bit.ly/489qmqZ #EmployeeSpotlight #Genetics #ZebrafishResearch #InVivoBiosystems #ScientificInnovation #GenomicScience #WomenInSTEM #PhD #GoTeam

🌟 Exciting news! The 2024 Nobel Prize in Physiology or Medicine has been awarded for groundbreaking research involving 𝘊𝘢𝘦𝘯𝘰𝘳𝘩𝘢𝘣𝘥𝘪𝘵𝘪𝘴 𝘦𝘭𝘦𝘨𝘢𝘯𝘴 (𝘊. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴), a vital organism that has significantly advanced our understanding of genetics, aging, toxicity and disease. At InVivo Biosystems, we take pride in leading the way in 𝘊. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴 research. By harnessing its unique genetic similarities to humans, we drive innovation in drug discovery and development. Our patented gene editing technologies, part of our RapidGen™ preclinical platform, effectively bridge the gap between genetic insights and therapeutic breakthroughs. As we celebrate this prestigious accolade, we eagerly anticipate the transformative potential that 𝘊. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴 hold for the future of research and medicine. 🧬✨ Discover more about the Nobel Prize and 𝘊. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴 as a model organism here: https://lnkd.in/g7wdJ2B8 #NobelPrize #Celegans #InVivoBiosystems #Biotech #Innovation #DiseaseModeling #RNA #Research

The InVivo Biosystems team had a great time at the Oregon Bioscience Association's Annual Biotech Summit, featuring the Innovation Showcase and Bio on the Vine! 🌟🍷 Beyond deepening our partnerships with Oregon State Economic Development agencies and Oregon Bio committees, we made exciting new connections with Federal Agencies. The summit's discussions and business pitches were all about advancing biotech and biomedical innovation through national policy frameworks, public-private partnerships, and so much more—laying the groundwork for future breakthroughs. 💡 We’re excited to keep driving innovation and look forward to seeing how these collaborations will shape the future! Kat McCormick, PhD | Sarah Cheesman, Ph.D. | Joseph Bruckner, PhD | Ally Wimberly #Biotech #Biotechnology #Innovation #InVivoBiosystems #BusinessOregon #OregonBio #FederalInnovation

On #WorldAlzheimersDay, we reflected on the urgency of finding solutions for this devastating disease. At InVivo Biosystems, we are proud to play a part in the ongoing fight against Alzheimer’s through our innovative RapidGen™ preclinical platform. RapidGen™ revolutionizes drug discovery by starting with AI-powered target selection, followed by the use of validated, humanized Alzheimer's Disease models and high-throughput phenotypic screening. This streamlined process accelerates the delivery of IND-enabling data, empowering pharmaceutical companies to make faster, more informed decisions—advancing potential treatments to the clinic without added financial strain. Learn more about how the RapidGen™ platform is accelerating preclinical development here: https://lnkd.in/gUH88Jbp #AlzheimersDisease #PreclinicalResearch #InVivoBiosystems #DrugDiscovery #DrugDevelopment #Innovation #BiotechInnovation #NeurodegenerativeDisease

🎉 We are thrilled to announce the well-deserved promotions of Marnie Preston, PhD and Joseph Bruckner, PhD, to Directors of Biology! Dr. Preston will be heading our genetics platform, while Dr. Bruckner will be leading assay development. Their leadership has been pivotal in advancing our RapidGen™ preclinical platform, which is transforming how we deliver robust IND enabling insights for our partners. Their combined expertise and dedication have been instrumental in driving our platform forward, and we’re confident that they will continue to propel InVivo Biosystems to new heights in innovation and discovery. Please join us in congratulating them on this fantastic achievement! 👏 #Leadership #Biotech #Innovation #InVivoBiosystems

🔬 At InVivo Biosystems, we are unwavering in our commitment to de-risking preclinical development and accelerating the journey from lab to clinic for life-saving therapies. Our latest innovation, MIC-Drop™, is a game-changer in this mission. As one of 10 patented technologies we've brought to market, MIC-Drop™’s multiplexed CRISPR capability is revolutionizing gene editing by drastically improving speed, efficiency, and accuracy while minimizing experimental bias. This breakthrough is particularly impactful for high-throughput target validation and enables more robust disease modeling for preclinical development. The impact? Faster, more confident decision-making that propels new treatments to patients in record time. 🚀 Learn more about MIC-Drop™ here: https://lnkd.in/ghtHTWYz #Pharma #Biopharma #Innovation #PreclinicalDevelopment #CRISPR #Biotech #InVivoBiosystems